Literature DB >> 8189760

Outcome of chronic idiopathic meningitis.

J E Smith1, A J Aksamit.   

Abstract

OBJECTIVE: To record long-term follow-up data on patients with chronic idiopathic meningitis.
DESIGN: We retrospectively reviewed the outcome of 49 patients who were examined at the Mayo Clinic between 1978 and 1990.
MATERIAL AND METHODS: For all patients, symptoms, signs, laboratory values, results of imaging studies, findings on biopsies, results of any empiric treatment, and results of autopsy, if applicable, were assessed. Some of these findings were stratified on the basis of good versus poor outcome of the patients and were analyzed statistically.
RESULTS: Of the 49 patients who fulfilled the criteria for chronic idiopathic meningitis, 10 had a cause identified after repeated studies, brain biopsy, or autopsy (8 of these had a neoplasm). Of 21 brain biopsies, 5(24%) yielded a diagnosis. Follow-up of the 39 undiagnosed cases showed that 33 (85%) had a good outcome despite an often prolonged illness. Two patients (5%) died of the meningeal process. Of the eight patients treated empirically with antituberculous medications, none responded. Corticosteroid therapy was effective in 52% of the patients thus treated, but it did not influence the outcome.
CONCLUSION: In this study, 85% of undiagnosed cases of chronic meningitis were benign. No clinical or laboratory findings predicted those patients who had a fatal outcome. In our study population, the most useful empiric therapy was corticosteroids rather than antituberculous medications.

Entities:  

Mesh:

Year:  1994        PMID: 8189760     DOI: 10.1016/s0025-6196(12)62246-0

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  12 in total

1.  Evaluation and treatment of chronic meningitis.

Authors:  Kelly J Baldwin; Joseph R Zunt
Journal:  Neurohospitalist       Date:  2014-10

2.  A 20-year-old woman with headache and transient numbness.

Authors:  Kenneth L Tyler; Erik C B Johnson; David S Cantu; Barbara L Haller
Journal:  Neurohospitalist       Date:  2013-04

Review 3.  Chronic Meningitis.

Authors:  Kiran T Thakur; Michael R Wilson
Journal:  Continuum (Minneap Minn)       Date:  2018-10

4.  Open biopsy in patients with acute progressive neurologic decline and absence of mass lesion.

Authors:  Albert J Schuette; Jason S Taub; Costas G Hadjipanayis; Jeffrey J Olson
Journal:  Neurology       Date:  2010-08-03       Impact factor: 9.910

5.  Isolated central nervous system histoplasmosis in an immunocompetent patient: 53-month hiatus to diagnosis and treatment.

Authors:  Joseph R Berger; Richard N Greenberg
Journal:  J Neurovirol       Date:  2010-11-09       Impact factor: 2.643

Review 6.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

7.  Chronic Meningitis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-07       Impact factor: 3.972

Review 8.  Chronic meningitis.

Authors:  Bruce A Cohen
Journal:  Curr Neurol Neurosci Rep       Date:  2005-11       Impact factor: 6.030

9.  Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference Proceedings.

Authors:  Christopher M Perrone; Robert P Lisak; Ethan I Meltzer; Peter Sguigna; Etsegenet Tizazu; Dina Jacobs; Esther Melamed; Ashlea Lucas; Leorah Freeman; Gabriel Pardo; Andrew Goodman; Edward J Fox; Kathleen Costello; Matthew S Parsons; Scott S Zamvil; Elliot M Frohman; Teresa C Frohman
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-06-13

10.  Chronic Meningitis: Simplifying a Diagnostic Challenge.

Authors:  Kelly Baldwin; Chris Whiting
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 6.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.